List of Tuxarin Er drug patents

Tuxarin Er is owned by Mainpointe.

Tuxarin Er contains Chlorpheniramine Maleate; Codeine Phosphate.

Tuxarin Er has a total of 2 drug patents out of which 0 drug patents have expired.

Tuxarin Er was authorised for market use on 22 June, 2015.

Tuxarin Er is available in tablet, extended release;oral dosage forms.

Tuxarin Er can be used as treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets.

The generics of Tuxarin Er are possible to be released after 03 January, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066942 MAINPOINTE Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Jan, 2032

(8 years from now)

US9107921 MAINPOINTE Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Jan, 2032

(8 years from now)

Do you want to check out TUXARIN ER patents from before 2022?

Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

TUXARIN ER family patents

8

United States

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in